Total Payments
$10,079
2023 Payments
$18.44
Companies
5
Transactions
58
Payment Breakdown by Category
Consulting$4,390 (43.6%)
Research$2,936 (29.1%)
Travel$2,074 (20.6%)
Food & Beverage$679.12 (6.7%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $4,390 | 1 | 43.6% |
| Unspecified | $2,936 | 26 | 29.1% |
| Travel and Lodging | $2,074 | 11 | 20.6% |
| Food and Beverage | $679.12 | 20 | 6.7% |
Payments by Type
General
$7,143
32 transactions
Research
$2,936
26 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Gilead Sciences, Inc. | $6,752 | 23 | $0 (2019) |
| Merck Sharp & Dohme Corporation | $1,490 | 16 | $0 (2020) |
| ViiV Healthcare Company | $1,129 | 14 | $0 (2018) |
| GlaxoSmithKline, LLC. | $689.88 | 4 | $0 (2017) |
| Ferring Pharmaceuticals Inc. | $18.44 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $18.44 | 1 | Ferring Pharmaceuticals Inc. ($18.44) |
| 2020 | $1,332 | 12 | Merck Sharp & Dohme Corporation ($1,332) |
| 2019 | $1,117 | 8 | Gilead Sciences, Inc. ($1,117) |
| 2018 | $6,428 | 24 | Gilead Sciences, Inc. ($5,635) |
| 2017 | $1,184 | 13 | GlaxoSmithKline, LLC. ($689.88) |
All Payment Transactions
58 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 05/22/2023 | Ferring Pharmaceuticals Inc. | REBYOTA (Biological) | Food and Beverage | In-kind items and services | $18.44 | General |
| Category: GASTROENTEROLOGY | ||||||
| 01/16/2020 | Merck Sharp & Dohme Corporation | MK-8591A (Drug) | Food and Beverage | Cash or cash equivalent | $5.57 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 01/15/2020 | Merck Sharp & Dohme Corporation | MK-8591A (Drug) | Travel and Lodging | In-kind items and services | $66.78 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 01/15/2020 | Merck Sharp & Dohme Corporation | MK-8591A (Drug) | Food and Beverage | In-kind items and services | $64.99 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 01/15/2020 | Merck Sharp & Dohme Corporation | MK-8591A (Drug) | Food and Beverage | In-kind items and services | $48.49 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 01/15/2020 | Merck Sharp & Dohme Corporation | MK-8591A (Drug) | Food and Beverage | In-kind items and services | $39.93 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 01/15/2020 | Merck Sharp & Dohme Corporation | MK-8591A (Drug) | Food and Beverage | Cash or cash equivalent | $38.12 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 01/14/2020 | Merck Sharp & Dohme Corporation | MK-8591A (Drug) | Travel and Lodging | In-kind items and services | $474.70 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 01/14/2020 | Merck Sharp & Dohme Corporation | MK-8591A (Drug) | Travel and Lodging | In-kind items and services | $226.60 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 01/14/2020 | Merck Sharp & Dohme Corporation | MK-8591A (Drug) | Food and Beverage | In-kind items and services | $149.37 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 01/14/2020 | Merck Sharp & Dohme Corporation | MK-8591A (Drug) | Travel and Lodging | Cash or cash equivalent | $82.18 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 01/14/2020 | Merck Sharp & Dohme Corporation | MK-8591A (Drug) | Food and Beverage | Cash or cash equivalent | $39.25 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 01/13/2020 | Merck Sharp & Dohme Corporation | MK-8591A (Drug) | Travel and Lodging | In-kind items and services | $95.57 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 12/07/2019 | Gilead Sciences, Inc. | — | — | Cash or cash equivalent | $50.00 | Research |
| Study: A Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhibitor GS-6207 in Combination with Other Antiretroviral Agents in People Living with HIV | ||||||
| 12/07/2019 | Gilead Sciences, Inc. | — | — | Cash or cash equivalent | $41.07 | Research |
| Study: A Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhibitor GS-6207 in Combination with Other Antiretroviral Agents in People Living with HIV | ||||||
| 12/07/2019 | Gilead Sciences, Inc. | — | — | Cash or cash equivalent | $35.94 | Research |
| Study: A Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhibitor GS-6207 in Combination with Other Antiretroviral Agents in People Living with HIV | ||||||
| 12/07/2019 | Gilead Sciences, Inc. | — | — | Cash or cash equivalent | $15.40 | Research |
| Study: A Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhibitor GS-6207 in Combination with Other Antiretroviral Agents in People Living with HIV | ||||||
| 12/06/2019 | Gilead Sciences, Inc. | — | — | Cash or cash equivalent | $506.60 | Research |
| Study: A Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhibitor GS-6207 in Combination with Other Antiretroviral Agents in People Living with HIV | ||||||
| 12/06/2019 | Gilead Sciences, Inc. | — | — | Cash or cash equivalent | $213.23 | Research |
| Study: A Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhibitor GS-6207 in Combination with Other Antiretroviral Agents in People Living with HIV | ||||||
| 12/06/2019 | Gilead Sciences, Inc. | — | — | Cash or cash equivalent | $156.67 | Research |
| Study: A Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhibitor GS-6207 in Combination with Other Antiretroviral Agents in People Living with HIV | ||||||
| 12/06/2019 | Gilead Sciences, Inc. | — | — | Cash or cash equivalent | $98.03 | Research |
| Study: A Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhibitor GS-6207 in Combination with Other Antiretroviral Agents in People Living with HIV | ||||||
| 05/24/2018 | Gilead Sciences, Inc. | — | Consulting Fee | Cash or cash equivalent | $4,390.00 | General |
| 05/24/2018 | Gilead Sciences, Inc. | — | Travel and Lodging | In-kind items and services | $95.84 | General |
| 05/24/2018 | Gilead Sciences, Inc. | — | Travel and Lodging | In-kind items and services | $68.91 | General |
| 05/24/2018 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $39.43 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhibitor GS-6207 in Combination with Other Antiretroviral Agents in People Living with HIV | Gilead Sciences, Inc. | $1,117 | 8 |
| A PHASE III, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, NON-INFERIORITY | ViiV Healthcare Company | $793.53 | 9 |
| A Phase IIIb, randomized, multicenter, parallel group, non inferiority, open label study evaluating the efficacy, safety, and tolerability of long acting cabotegravir plus long acting rilpivirine administered every 8 weeks or every 4 weeks in HIV 1 infect | GlaxoSmithKline, LLC. | $689.88 | 4 |
| A Phase IIIb, randomized, multicenter, parallel group, non inferiority, open label study evaluating the efficacy, safety, and tolerability of long acting cabotegravir plus long acting rilpivirine administered every 8 weeks or every 4 weeks in HIV 1 infect | ViiV Healthcare Company | $316.85 | 4 |
| A PHASE IIIB, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, NON-INFERIORITY | ViiV Healthcare Company | $18.67 | 1 |
About Dr. Deborah Goldstein, MD
Dr. Deborah Goldstein, MD is a Infectious Disease healthcare provider based in Washington, District of Columbia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/08/2008. The National Provider Identifier (NPI) number assigned to this provider is 1457502460.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Deborah Goldstein, MD has received a total of $10,079 in payments from pharmaceutical and medical device companies, with $18.44 received in 2023. These payments were reported across 58 transactions from 5 companies. The most common payment nature is "Consulting Fee" ($4,390).
Ad
Practice Information
- Specialty Infectious Disease
- Location Washington, DC
- Active Since 10/08/2008
- Last Updated 11/07/2013
- Taxonomy Code 207RI0200X
- Entity Type Individual
- NPI Number 1457502460
Products in Payments
- MK-8591A (Drug) $1,332
- MK-8591 (Drug) $158.23
- REBYOTA (Biological) $18.44
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Infectious Disease Doctors in Washington
Dr. Robert Gasser, Md, MD
Infectious Disease — Payments: $922,181
Infectious Disease $922,181
Princy Kumar
Infectious Disease — Payments: $417,633
Infectious Disease $417,633
Dr. Jose Chavez, Md, MD
Infectious Disease — Payments: $293,279
Infectious Disease $293,279
Dr. Gebeyehu Teferi, M.d, M.D
Infectious Disease — Payments: $97,206
Infectious Disease $97,206
Dawn Fishbein, Md, MD
Infectious Disease — Payments: $24,671
Infectious Disease $24,671
Dr. Glenn Wortmann, M.d, M.D
Infectious Disease — Payments: $14,236
Infectious Disease $14,236